Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release


Posted on: 22 Jun 18

Cambridge, UK., 21st June 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, today announces that its abstract supporting the application of its proprietary Arestat™ technology platform to enable a superfast insulin product has been accepted for a poster presentation at the upcoming American Diabetes Association 78th Scientific Sessions, from June 22 - 26, 2018 in Orlando, FL, USA.


During this meeting, Professor Thomas Pieber, a key member of Arecor’s Scientific Advisory Board, will present a poster detailing the pre-clinical results of Arecor’s superfast insulin.


“We are very pleased to be presenting details of our proprietary superfast insulin programme for the first time at this year’s ADA Scientific Sessions and to an international audience of experts dedicated to improving the life of people with diabetes.  These results further confirm the potential of our proprietary formulation technology to deliver a next generation superfast acting insulin  and to improve the treatment options and quality of life of people living with diabetes,” commented Dr Sarah Howell, Chief Executive Officer of Arecor.  


POSTER # 95-LB: Pharmacokinetic and Pharmacodynamic Properties of a Novel "Superfast" Insulin AspartFormulation 

Presenting Author:          Professor Thomas Pieber             

Date and time:                  Monday June 25, 2018 12:00 PM – 01:00 PM

Location:                            WA4-WB2 (Poster Hall) 


About the ADA Scientific Sessions 

The American Diabetes Association’s Scientific Sessions offers researchers and health care professionals around the world an exclusive opportunity to share ideas and gain knowledge about the recent advances in diabetes research, treatment, and care. Attendees will have access access to more than 2,800 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand their professional networks. For further information, please email:


About Arecor

Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.  Arecor's product portfolio also includes:


·        Stable aqueous glucagon for emergency and artificial pancreas use,

·        Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;

·        Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices, and

·        A series of undisclosed pre-clinical programmes.


In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.


About ArestatTM

Arecor has significant experience and a proven track record in applying the ArestatTM formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.


For more information, please contact:




Arecor Limited

Dr Sarah Howell, Chief Executive

Tel: +44 (0) 1223 426 060

Dr Laura AS Ciccolini, Director BD & L

Tel: +44 (0) 1223 426 060


Mob: +44 (0) 7900 784 220




Mr Tarquin Edwards



Mob: +44 (0) 7879 458 364


Editor's Details

Mike Wood

Last updated on: 22/06/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.